Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 1,918,188 |
|
|||||
| News | - | ||||||
| Day High | 2.185 | Low High |
|||||
| Day Low | 1.99 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Coherus BioSciences Inc | CHRS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.115 | -5.36% | 2.03 | 19:55:29 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 2.15 | 1.99 | 2.185 | 2.00 | 2.145 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 6,740 | 1,918,188 | $ 2.10 | $ 4,027,283 | - | 1.4301 - 8.34 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:55:29 | formt | 347 | $ 2.03 | USD |
Coherus BioSciences Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 221.61M | 111.36M | - | 257.24M | -237.89M | -2.14 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Coherus BioSciences News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CHRS Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.46 | 2.52 | 1.99 | 2.24 | 1,703,435 | -0.43 | -17.48% |
| 1 Month | 2.52 | 2.64 | 1.99 | 2.36 | 2,065,629 | -0.49 | -19.44% |
| 3 Months | 2.33 | 2.87 | 1.925 | 2.36 | 2,804,551 | -0.30 | -12.88% |
| 6 Months | 3.70 | 3.73 | 1.4301 | 2.52 | 5,046,412 | -1.67 | -45.14% |
| 1 Year | 8.29 | 8.34 | 1.4301 | 3.32 | 4,039,705 | -6.26 | -75.51% |
| 3 Years | 14.42 | 19.32 | 1.4301 | 5.71 | 1,960,706 | -12.39 | -85.92% |
| 5 Years | 14.66 | 23.91 | 1.4301 | 9.18 | 1,627,703 | -12.63 | -86.15% |
Coherus BioSciences Description
| Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States. |
